Restless legs syndrome is common. While many patients are simply inconvenienced, others suffer greatly from wakefulness and disturbed sleep. The condition is readily recognised by history and examination and perhaps simple investigations. Secondary causes should be excluded. mild symptoms can be managed without drugs, but severe symptoms may require a dopamine agonist. Treatment is usually effective but may present some practical difficulties.
Introduction
About 5-15% of the population are affected by restless legs syndrome. 1 Probably the earliest description was written in 1683 in 'Two discourses concerning the soul of brutes':
... whilst they would indulge in sleep, in their beds, immediately follow leapings up of the tendons in their arms and legs, with cramps, and such unquietness and flying about of their members, that the sick can no more sleep, than those on the rack. 2 This captures the elements of restless legs syndrome: sensory discomfort ('cramps'), motor restlessness ('unquietness'), the associated involuntary movements during sleep and wakefulness ('flying about of their members'), aggravation by night and rest ('in their beds'), sleep disruption, and the tortured condition of the worst affected ('on the rack').
Restless legs syndrome can begin at any age. Earlier, slower onset suggests hereditary restless legs syndrome and later, abrupt onset, secondary restless legs syndrome. At first exacerbations and remissions occur, but then the tendency is for a static or chronic progressive course. Although some people have severe symptoms, most people do not require drug treatment.
Diagnosis and classification
The clinical evaluation of restless legs syndrome, particularly the patient's history, is very important. The diagnosis is based on criteria proposed at a consensus conference held at the National Institutes of Health in the USA (see box). 1 The condition is classified as 'idiopathic' or secondary to several other conditions (Table 1) .
Essential diagnostic criteria
Typically, patients complain of limb (usually leg) discomfort at rest, an urge to move the affected part, and unpleasant sensory symptoms. They often find it hard to describe the sensations, or say 'creeping, crawling, itching, burning, searing, tugging, pulling, drawing, aching, hot and cold, electric current-like, restless or painful'. These sensations are felt deep in muscle or bone, seldom in a joint. The whole limb or part of it may be involved, even unilaterally. In about half the cases, arms and legs are affected, but sole involvement of the arms is uncommon. Occasionally, the sensory symptoms are absent.
Usually, the symptoms begin after the patient has been lying or sitting quietly. Symptoms only on sitting are very uncommon.
The more mentally rested and physically quiet the patient is, the more intense the symptoms. They can last for a few minutes or an hour. 
Associated features
Over 90% of patients have insomnia -usually trouble initiating or maintaining sleep. The neurological examination is usually normal although there may be signs of neuropathy in some secondary cases. There is an association between restless legs syndrome and cardiovascular disease. 3 Clinical examination is mainly directed at identifying causes of secondary restless legs syndrome (Table 1) .
Investigations
Laboratory testing is fairly limited unless a secondary cause is antidepressants with anticholinergic effects may worsen restless legs syndrome.
As the condition often fluctuates over time, the mildly affected patient may be able to use medication intermittently.
Continuous treatment should be reserved for more severely affected individuals. Generally, idiopathic restless legs syndrome does not resolve.
Dopamine agonists
Low-dose dopamine agonists are largely replacing levodopa as first-line treatment for restless legs syndrome because of ease of management and better efficacy. Cabergoline has the advantage of a very long half-life and had superior efficacy to levodopa in the first large randomised controlled trial comparing two dopaminergic therapies in restless legs syndrome. 5 Of the newer non-ergot derived dopamine agonists, ropinirole has been the most extensively studied 6 , followed by pramipexole. 7 If there are significant daytime symptoms, patients may need multiple doses or long-acting preparations. As a general rule, doses should start low and be increased gradually to avoid adverse effects. It is important to keep doses low as there is no extra benefit from the higher doses used in Parkinson's disease, and because of the risk of augmentation with higher doses. Another problem is rebound, in which the symptoms of restless legs syndrome reappear after the drug has worn off. This is similar to 'wearing off' in Parkinson's disease and manifests as early morning or late night symptoms. Rebound is related to the half-life of the drug, so it is best to use a long-acting preparation, multiple dosing or switch to cabergoline.
Adverse effects
Concerns have arisen over the use of ergot-derived dopamine Common adverse effects of dopamine agonists, particularly at the start of treatment, are nausea and dizziness (due to postural hypotension). Impulse control disorders including pathological gambling and hypersexuality are increasingly being recognised.
Another concern is pathological daytime somnolence occurring as 'sleep attacks' which may cause motor vehicle accidents.
While these adverse effects seem dose related, they may occur with the relatively low doses used in restless legs syndrome, so awareness and caution are necessary.
Opioid treatment may be complicated by sedation and constipation. It has the potential for abuse, dependency and withdrawal, so occasional use is preferable. Caution should be exercised in prolonged treatment.
Conclusion
Restless legs syndrome is a common but under-recognised disorder. For patients with mild symptoms, no drug treatment may be necessary. For patients with severe symptoms, dopamine agonists are the first-line treatment when a drug is needed. Some patients can be managed with intermittent therapy.
